159711_CD
Reed_NN
Report_NN
103-142_CD
7_CD
3_CD
06_CD
12:05_CD
Page_NN
117_CD
Reed_NN
Elsevier_NN
Annual_JJ
Reports_NN
and_PHC
Financial_NN
Statements_NOMZ
2005_CD
117_CD
19_CD
Reconciliations_NOMZ
to_PIN
previous_JJ
GAAP_NN
continued_VBD
2004_CD
As_IN
at_PIN
31_CD
December_NN
Note_NN
m_NN
Shareholders_NN
equity_NOMZ
under_IN
previous_JJ
GAAP_NN
1,199_CD
Adjustments_NOMZ
:_:
Share_NN
of_PIN
IFRS_NN
adjustments_NOMZ
in_PIN
joint_JJ
ventures_NN
i_FPP1
439_FW
Dividends_NN
ii_FW
120_CD
Shareholders_NN
equity_NOMZ
under_IN
IFRS_NN
880_CD
i_FPP1
Details_NN
of_PIN
the_DT
IFRS_NN
adjustments_NOMZ
made_VBD
to_PIN
the_DT
Reed_NN
Elsevier_NN
combined_VBN
figures_NN
are_VPRT [PASS]
presented_VBN
in_PIN
note_NN
33_CD
to_PIN
the_DT
combined_VBN
financial_JJ
statements_NOMZ
._.
ii_FW
Reversal_NN
of_PIN
proposed_VBN [SUAV]
dividends_NN
not_XX0
declared_VBN [PUBV]
by_PIN
31_CD
December_NN
2004_CD
._.
Under_IN
IFRS_NN
the_DT
carrying_VBG
value_NN
of_PIN
investments_NOMZ
in_PIN
joint_JJ
ventures_NN
and_CC
external_JJ
payables_NN
at_PIN
31_CD
December_NN
2004_CD
were_VBD [BEMA]
439m_CD
and_CC
120m_CD
lower_JJ
respectively_RB
,_,
compared_VBN [PASTP]
to_PIN
the_DT
figures_NN
reported_VBN [PUBV]
under_IN
previous_JJ
GAAP_NN
._.
As_IN
at_PIN
the_DT
IFRS_NN
transition_NOMZ
date_NN
of_PIN
1_CD
January_NN
2004_CD
,_,
shareholders_NN
equity_NOMZ
was_VBD [BEMA]
417m_CD
lower_JJ
under_IN
IFRS_NN
than_PIN
under_IN
previous_JJ
GAAP_NN
due_JJ
to_PIN
the_DT
share_NN
of_PIN
IFRS_NN
adjustments_NOMZ
in_PIN
joint_JJ
ventures_NN
of_PIN
527m_JJ
and_CC
the_DT
reversal_NN
of_PIN
proposed_VBN [SUAV]
dividends_NN
of_PIN
110m_CD
._.
20_CD
Post_NN
balance_NN
sheet_NN
event_NN
On_PIN
14_CD
February_NN
2006_CD
,_,
Reed_NN
Elseviers_NN
Group_NN
plc_NN
declared_VBD [PUBV]
a_DT
dividend_NN
to_PIN
Reed_NN
Elsevier_NN
PLC_NN
of_PIN
150m_CD
._.
21_CD
Principal_NN
joint_JJ
ventures_NN
%_NN
holding_VBG [PRIV] [WZPRES]
Reed_NN
Elsevier_NN
Group_NN
plc_NN
Incorporated_NN
and_CC
operating_VBG
in_PIN
Great_NN
Britain_NN
10,000_CD
ordinary_JJ
R_NN
shares_NN
100_CD
%_NN
1-3_CD
Strand_NN
10,000_CD
ordinary_JJ
E_NN
shares_NN
London_NN
WC2N_NN
5JR_NN
100,000_CD
7.5_CD
%_NN
cumulative_JJ
preference_NN
non_NN
voting_VBG [SUAV] [WZPRES]
shares_NN
100_CD
%_NN
Holding_VBG [PRIV] [WZPRES]
company_NN
for_PIN
operating_VBG
businesses_NOMZ
involved_VBN [WZPAST]
in_PIN
science_NN
&_CC
medical_JJ
,_,
legal_JJ
,_,
educational_JJ
and_CC
business_NOMZ
publishing_GER
Equivalent_NN
to_PIN
a_DT
50_CD
%_NN
equity_NOMZ
interest_NN
Elsevier_NN
Reed_NN
Finance_NN
BV_NN
Incorporated_NN
in_PIN
the_DT
Netherlands_NN
133_CD
ordinary_JJ
R_NN
shares_NN
100_CD
%_NN
Radarweg_NN
29_CD
205_CD
ordinary_JJ
E_NN
shares_NN
1043_CD
NX_NN
Amsterdam_NN
,_,
The_DT
Netherlands_NN
Holding_GER
company_NN
for_PIN
financing_GER
businesses_NOMZ
Equivalent_NN
to_PIN
a_DT
39_CD
%_NN
equity_NOMZ
interest_NN
The_DT
E_NN
shares_NN
in_PIN
Reed_NN
Elsevier_NN
Group_NN
plc_NN
and_PHC
Elsevier_NN
Reed_NN
Finance_NN
BV_NN
are_VPRT [BYPA]
owned_VBN
by_PIN
Reed_NN
Elsevier_NN
NV_NN
._.
22_CD
Principal_NN
subsidiary_NN
%_NN
holding_VBG [PRIV] [WZPRES]
Reed_NN
Holding_GER
BV_NN
Incorporated_NN
in_PIN
the_DT
Netherlands_NN
41_CD
ordinary_JJ
shares_NN
100_CD
%_NN
Radarweg_NN
29_CD
1043_CD
NX_NN
Amsterdam_NN
,_,
The_DT
Netherlands_NN
Reed_NN
Holding_GER
BV_NN
owns_VPRT
4,679,249_CD
shares_NN
of_PIN
a_DT
separate_JJ
class_NN
in_PIN
Reed_NN
Elsevier_NN
NV_NN
,_,
giving_VBG
Reed_NN
Elsevier_NN
PLC_NN
a_DT
5.8_CD
%_NN
indirect_JJ
equity_NOMZ
interest_NN
in_PIN
Reed_NN
Elsevier_NN
NV_NN
._.
